EGFR and colorectal carcinoma: To account for spatial and temporal changes, the genomic profiles of CRC patients should be evaluated repeatedly during the course of therapy and liquid biopsies could play a role for determinations that are more representative of the specific molecular scenario of a patient at the time of anti-EGFR therapy selection [7, 15].